Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 7,057 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Completed No phase listed Observational

Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

NCT00888589
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Michael O'Connor
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 25, 2026, 11:06 PM EDT
Not listed No phase listed Observational

TME Neoadjuvant Breast Registry

NCT02596724
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Genomic and/or molecular testing of blood or tissue
Other
Lead sponsor
Targeted Medical Education
Other
Eligibility
18 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Los Gatos, California • Allentown, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 25, 2026, 11:06 PM EDT
Recruiting Phase 1 Interventional

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT04119024
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
Anusha Kalbasi
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Acupuncture for Sleep Disruption in Cancer Survivors

NCT01162018
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Breast Cancer
Interventions
acupuncture, placebo
Procedure · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 25, 2026, 11:06 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 25, 2026, 11:06 PM EDT
Completed No phase listed Observational

Autologous Fat Grafting in Radiated Soft Tissue Reconstruction

NCT05890196
View directory record Official record
Conditions
Breast Cancer, Radiation Fibrosis, Fat Grafting
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 25, 2026, 11:06 PM EDT
Recruiting Not applicable Interventional

Definitive Radiation Therapy for Inoperable Breast Cancer

NCT07122713
View directory record Official record
Conditions
Breast Cancer, Breast Adenocarcinoma
Interventions
Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor, Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes
Radiation
Lead sponsor
Alexander Stessin
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 11:06 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction

NCT05316324
View directory record Official record
Conditions
Breast Cancer
Interventions
Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM), Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 11:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts

NCT04534010
View directory record Official record
Conditions
Breast Cancer
Interventions
NACgraft
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 11:06 PM EDT
Terminated Phase 1 Interventional

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

NCT04116320
View directory record Official record
Conditions
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions
Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
Device · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 25, 2026, 11:06 PM EDT
Suspended Phase 1 Interventional

Pilot Trial of Preop Partial Radiation in Breast Cancer Patients

NCT07178665
View directory record Official record
Conditions
Early-stage Breast Cancer, Breast Carcinoma, DCIS
Interventions
Radiation: Accelerated Partial Breast Irradiation (APBI)
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 11:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

NCT00182767
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
ixabepilone, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Farmington, Connecticut • Albany, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study

NCT02954900
View directory record Official record
Conditions
Breast Neoplasms
Interventions
RealRisks, BNAV
Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Breast Cancer Screening in Chinese Immigrants

NCT05089292
View directory record Official record
Conditions
Screening Mammogram
Interventions
Narrative breast health education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 25, 2026, 11:06 PM EDT
Active, not recruiting Phase 2 Interventional

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

NCT04445844
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
Interventions
Pelareorep, Quality-of-Life Assessment, Questionnaire Administration, Retifanlimab
Biological · Other
Lead sponsor
Mridula George, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 25, 2026, 11:06 PM EDT
Completed Early Phase 1 Interventional Results available

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

NCT03004534
View directory record Official record
Conditions
Breast Cancer Female
Interventions
darolutamide
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Redondo Beach, California • Santa Maria, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 25, 2026, 11:06 PM EDT
Terminated Phase 1Phase 2 Interventional

NBE-002 in Patients With Advanced Solid Tumors

NCT04441099
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer
Interventions
NBE-002
Drug
Lead sponsor
NBE-Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 25, 2026, 11:06 PM EDT
Completed No phase listed Observational

Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies

NCT00341263
View directory record Official record
Conditions
Normal Pregnancy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 25, 2026, 11:06 PM EDT
Terminated Phase 2 Interventional

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

NCT01698281
View directory record Official record
Conditions
Breast Cancer
Interventions
AEZS-108, SCCC, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 25, 2026, 11:06 PM EDT
Terminated Early Phase 1 Interventional

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

NCT03361800
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions
Entinostat
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 25, 2026, 11:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892
View directory record Official record
Conditions
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
Interventions
disitamab vedotin, tucatinib
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
77
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 11:06 PM EDT
Withdrawn Phase 2 Interventional

Fulvestrant + Neratinib In Breast Cancer

NCT04901299
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 25, 2026, 11:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Ohio State University (OSU) SCREEN Community Program

NCT06666192
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
Interventions
Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
Other · Behavioral · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 25, 2026, 11:06 PM EDT
Completed Phase 2 Interventional

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

NCT00077363
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
tipifarnib, capecitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 25, 2026, 11:06 PM EDT